|
AstraZeneca PLC on Thursday said Wainua, a cardiovascular drug that it is developing in partnership with Ionis Pharmaceuticals Inc, did not meet its primary endpoint in a phase III trial. AstraZeneca shares were down 9.9% to 12,834.00 pence in London early Thursday following the announcement, wiping some £20 billion in market value from the FTSE 100 stock. Ionis shares were quoted down 5.0% to €71.28 in Frankfurt. The Cambridge, England based pharmaceutical maker said Wainua, whose generic name is eplontersen, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy. The drug didn’t meet its primary efficacy endpoint in terms of mortality or cardiovascular clinical events up to 140 weeks, compared to a placebo. The safety profile was consistent with earlier results. ‘Although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients worldwide suffering from this progressive and often fatal condition,’ said Sharon Barr, executive vice president of BioPharmaceuticals research and development at AstraZeneca. AstraZeneca said it and Carlsbad, California-based partner Ionis will analyse the full data set to better understand the test results. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
